ERBB2 kinase domain mutation in the lung squamous cell carcinoma
Authors:
- Young Hwa SoungYSYoung Hwa Soung
- Su Young KimSKSu Young Kim
- Suk Woo NamSNSuk Woo Nam
- Won Sang ParkWPWon Sang Park
- Young Pil WangYWYoung Pil Wang
- Keon Hyun JoKJKeon Hyun Jo
- Seok Whan MoonSMSeok Whan Moon
- Sang Yong SongSSSang Yong Song
- Jung Young LeeJLJung Young Lee
- Nam Jin YooNYNam Jin Yoo
- Sug Hyung LeeSLSug Hyung Lee
- 1 June 2006
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 237 (1) , 89-94
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Somatic Mutations of the HER2 Kinase Domain in Lung AdenocarcinomasCancer Research, 2005
- Absence of EGFR mutation in the kinase domain in common human cancers besides non‐small cell lung cancerInternational Journal of Cancer, 2004
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- The discovery of receptor tyrosine kinases: targets for cancer therapyNature Reviews Cancer, 2004
- Toward Customized Trastuzumab in HER-2/neu-Overexpressing Non-Small-Cell Lung CancersJournal of Clinical Oncology, 2004
- The Protein Kinase Complement of the Human GenomeScience, 2002
- Protein kinases — the major drug targets of the twenty-first century?Nature Reviews Drug Discovery, 2002
- Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptorBiochemistry, 1987